Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy
-
- Taisei Keitoku
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Nobuharu Tamaki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Masayuki Kurosaki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Kento Inada
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Sakura Kirino
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Naoki Uchihara
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Keito Suzuki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Yuki Tanaka
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Haruka Miyamoto
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Shun Ishido
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Michiko Yamada
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Tsubasa Nobusawa
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Hiroaki Matsumoto
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Mayu Higuchi
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Kenta Takaura
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Shohei Tanaka
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Chiaki Maeyashiki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Shun Kaneko
- Department of Gastroenterology and Hepatology Tokyo Medical and Dental University Tokyo Japan
-
- Yutaka Yasui
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Yuka Takahashi
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Kaoru Tsuchiya
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Hiroyuki Nakanishi
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
-
- Yasuhiro Asahina
- Department of Gastroenterology and Hepatology Tokyo Medical and Dental University Tokyo Japan
-
- Ryuichi Okamoto
- Department of Gastroenterology and Hepatology Tokyo Medical and Dental University Tokyo Japan
-
- Namiki Izumi
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
Abstract
<jats:title>Abstract</jats:title><jats:p>The number of patients with fatty liver has been increasing worldwide; however, the significance of fatty liver in patients with chronic hepatitis B who are receiving nucleic acid analog (NA) therapy remains unclear. Thus, we aimed to determine whether fatty liver affects the development of hepatocellular carcinoma (HCC) in patients receiving NA therapy. This study included 445 patients who received NA therapy, and the development of HCC was investigated. The<jats:italic>primary outcome</jats:italic>was the association between fatty liver and HCC development. During a mean follow‐up period of 7.4 years, 46 patients (10.3%) developed HCC. No significant difference in the cumulative incidence of HCC was observed between patients with fatty liver and those without (<jats:italic>p</jats:italic> = 0.17). Multivariable analysis for age, gender, platelet count, alanine aminotransferase level at 1 year following NA therapy, and fatty liver revealed that the presence of fatty liver was not a significant factor for HCC development (hazard ratio [HR]: 0.96, 95% confidence interval [CI]: 0.5–1.9). In another multivariable analysis for advanced fibrosis, gender, and fatty liver, advanced fibrosis was found to be a significant factor for HCC development (HR: 9.50, 95% CI: 5.1–18) but not fatty liver (HR: 0.90, 95% CI: 0.5–1.7). In conclusion, in patients with chronic hepatitis B who received NA therapy, advanced fibrosis was found to be an important risk factor for HCC development but not fatty liver, suggesting the importance of providing treatment before the progression of liver fibrosis regardless of the presence of fatty liver.</jats:p>
Journal
-
- Journal of Viral Hepatitis
-
Journal of Viral Hepatitis 30 (4), 297-302, 2023-01-24
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360861707394018688
-
- ISSN
- 13652893
- 13520504
-
- Data Source
-
- Crossref
- KAKEN